52 results about "Inflammatory genes" patented technology

The invention discloses application of naringenin in preparation of a medicine for preventing and treating diseases caused by pseudorabies virus, and belongs to the technical field of biological medicine. The naringenin has good anti-PRV activity in vivo and in vitro. The naringenin can inhibit virus proliferation of the pseudorabies virus in an intracellular replication stage, reduce expression of PRV gB protein, lower expression of TLR4 and P65 protein to inhibit activation of an NF-kB pathway and lower expression of an inflammatory gene, and reduce nucleation of the NF-kB / P65 protein to achieve anti-inflammatory and antiviral effects. In-vivo experiments prove that naringenin can delay the disease time of mice, reduce the virus load in organs of the mice infected by PRV and relieve pathological changes of tissues and organs of the mice, and in addition, the survival rate of the mice infected by viruses is improved by adjusting the serum cell factor level of the mice. The naringenin provides a new strategy for preventing and treating PRV infection.

The invention discloses a frozen gel microneedle as well as a preparation method and application thereof, the preparation method comprises the following steps: (1) adding PBS (Phosphate Buffer Solution) into a brown bottle filled with an initiator LAP, and heating and stirring in a water bath at 40-50 DEG C for 15 minutes to obtain an initiator standard solution; (2) adding the initiator standard solution obtained in the step (1) into a brown glass bottle with HAMA, and stirring at room temperature in a dark place for 1 hour to obtain a photo-crosslinked HAMA hydrogel solution; (3) preparing a complete porous gel microneedle mold needle tip loaded with a gene therapy vector; (5) preparing a microneedle mold substrate; (6) freezing the microneedle mold with the formed needle tip and substrate to obtain a frozen gel microneedle array; and (7) demolding the frozen gel microneedle array to obtain the frozen gel microneedle. The obtained microneedle can be used for long-term collaborative treatment of chronic inflammatory diseases through percutaneous delivery of anti-inflammatory genes coded by CeNPs and rAAV2.

The invention belongs to the technical field of biology, and discloses application of wogonin in resisting siniperca chuatsi and frog iridovirus, the wogonin can effectively inhibit over-generation of ROS caused by MRV virus infection, and oxidative stress damage of host cells is relieved in a dose-dependent mode. The wogonin can be used for preventing and treating the siniperca chuatsi and frog iridovirus, the high expression state of a proinflammatory gene can be reduced, intestinal tissue damage induced by MRV infection can be relieved, proliferation of MRV in the micropterus salmoides is effectively inhibited, the MRV challenge survival rate of the micropterus salmoides is increased, a basis is provided for preparing a product for resisting the siniperca chuatsi and frog iridovirus from wogonin, and the wogonin has important application value. Meanwhile, the invention also discloses a medicine, a fish feed and a fish feed additive of the wogonin.

The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or anti-gen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-LI), CD8A, LAG3, and STAT1.

This disclosure provides a method for treating a cancer patient comprising administering to the patient a therapeutically effective amount of an anti-PD-1 antagonist, for example, an anti-PD-1 or anti-PD-L1 antibody, in combination with an indolamine 2,3-dioxygenase inhibitor, wherein the patient is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score. The high IFNγ inflammatory signature score is determined by measuring the expression of a panel of IFNγ-related inflammatory genes in a cancer sample obtained from the patient, wherein the gene panel comprises, for example, IFNγ, CXCL10, CXCL9, HLA-DRA, IDO1, and STAT1. In some respects, the gene panel also includes CCR5, CXCL11, GZMA, and PRF1.In some aspects, the genetic panel comprises CXCR6, TIGIT, PD-L1, PD-L2, LAG3, NKG7, PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1, CD276, HLA.DRB1, STAT1, HLA.E and TDO2.

The invention belongs to the field of bioengineering and neurotoxicity prevention and control, and particularly relates to a neurotoxicity antagonist screening and evaluating method based on a microorganism-intestine-brain axis. The screening method of the neurotoxicity antagonist comprises the following steps: establishment of a neurotoxicity animal model, verification of the neurotoxicity model, sequencing of intestinal flora and screening of key flora, coupling analysis of flora-cranial nerve indexes, verification of candidate microorganisms, screening of core bacterial metabolites, verification of the core bacterial metabolites and verification of the core bacterial metabolites. According to the method, through behavior-neurotransmitter-inflammation-gene / mitochondrial function multi-level index linkage, a reproducible recovery index (RI) index is established, and quantitative screening and grading judgment of candidate strains and metabolites of the candidate strains on nerve injury repair are achieved.

The disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antagonist, e.g., an anti-PD-1 or anti-PD-L1 antibody, in combination with an indoleamine 2,3-dioxygenase inhibitor, wherein the subject is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score. The high IFNγ inflammatory signature score is determined by measuring the expression of a panel of IFNγ related inflammatory genes in a cancer sample obtained from the subject, wherein the gene panel comprises, e.g., IFNγ, CXCL10, CXCL9, HLA-DRA, IDO1, and STAT1. In some aspects, the gene panel further comprises CCR5, CXCL11, GZMA, and PRF1. In some aspects, the gene panel comprises CXCR6, TIGIT, PD-L1, PD-L2, LAG3, NKG7, PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1, CD276, HLA.DRB1, STAT1, HLA.E, and TDO2.

The invention discloses prevention and treatment of diseases by stimulating TRPV1 + sensory nerves. Specifically, the invention discloses application of a substance for stimulating TRPV1 + sensory nerves in preparation of products for prevention, treatment or adjuvant treatment of inflammatory diseases, autonomic nerve dysfunction diseases or adrenal insufficiency diseases, and application of the substance for stimulating TRPV1 + sensory nerves in preparation of products for inhibiting proinflammatory cytokines and products for promoting anti-inflammatory cytokines. The TRPV1 ion channel agonist disclosed by the invention can obviously and effectively inhibit the expression of numerous proinflammatory cytokines and obviously improve the expression of anti-inflammatory cytokines IL10, so that not only is the physiological status of an inflammatory mouse obviously improved, but also the survival rate of the inflammatory mouse is obviously improved; meanwhile, the spleen function can be adjusted, expression of spleen pro-inflammatory genes is remarkably inhibited, generation of catecholamine is increased, and secretion of cortisol hormones is promoted. The invention has wide clinical application value in prevention and treatment of related diseases.

Glioblastomas (GBMs) are primary brain lesions with poor overall survival rates. Nearly 95% of patients die within 5 years of primary diagnosis. One of the leading factors to this high mortality is the inevitable nature of cancer recurrence. Disclosed herein are methods and compositions related to the identification and treatment of glioblastoma. Specifically, disclosed herein are methods for identifying progressing glioblastoma, and distinguishing it from pseudo-progression.

The invention belongs to the technical field of biological medicine, and particularly relates to application of recombinant Glypican 1 protein in treatment of non-alcoholic steatohepatitis. The Glypican 1 protein can treat non-alcoholic steatohepatitis for the first time, experiments prove that the Glypican 1 protein can improve liver lipid deposition, inflammation, fibrosis and other key pathological characteristics, and particularly, after the serum GPC1 level is increased, the Glypican 1 protein can inhibit high-fat and high-cholesterol diet induced mouse body weight increase, optimize the ratio of liver tissue weight to body weight, and improve the non-alcoholic steatohepatitis. The glucose tolerance and the insulin sensitivity are improved, so that the metabolic disorder is integrally improved; besides, the GPC1 accelerant can directly target macrophages, inhibit expression of pro-inflammatory genes (such as Tnf and Nos2) and relieve cascade reaction of liver inflammation, the anti-inflammatory effect is achieved by inhibiting an ERK1 / 2 phosphorylation pathway in mechanism, an innovative, efficient and flexible solution is provided for NASH treatment on the whole, and the defects of current treatment means are overcome.

The invention relates to the technical field of biology, and discloses a Lactobacillus paracasei KFY202407 and an application thereof in preparation of a preparation for preventing and treating vaginitis, the collection number of the Lactobacillus paracasei KFY202407 in China General Microbiological Culture Collection Center (CGMCC) is CGMCC NO: 30736, and the collection date is May 22, 2024. The lactobacillus paracasei KFY202407 disclosed by the invention can relieve inflammation of mice with vaginitis by regulating secretion of mouse serum inflammatory factors, activity of vaginal tissue MPO and expression conditions of vaginal tissue inflammatory genes. The microbial inoculum prepared from the lactobacillus paracasei KFY202407 has good stability and can be used as a medicine raw material.

The invention belongs to the technical field of medicines, and particularly relates to a golden flower and fruit extract for treating ulcerative colitis. According to the traditional Chinese medicine composition, natural medicine components are extracted from golden flower and fruit, the components can enhance the shielding guarantee effect of colonic mucosa, reduce inflammation gene expression, prevent colon shortening and improve the curative effect of ulcerative colitis, and the traditional Chinese medicine composition has a good application prospect.

Provided is stimulation of TRPV1+ and / or TRPA1+ sensory nerves for the prevention and treatment of diseases. Particularly provided is use of a substance for stimulating TRPV1+ and / or TRPA1+ sensory nerves in the prevention or treatment of inflammatory diseases, dysautonomia, or adrenal insufficiency, and in inhibiting the generation of pro-inflammatory cytokines and promoting the generation of anti-inflammatory cytokines. A TRPV1 and / or TRPA1 ion channel agonist can significantly effectively inhibit the expression of numerous pro-inflammatory cytokines and significantly improve the expression of the anti-inflammatory cytokine IL10, significantly improving both the physiological state and the survival rate of mice with inflammation. Moreover, the agonist can adjust spleen function, significantly inhibit the expression of pro-inflammatory genes in the spleen, increase the generation of catecholamine, and promote the secretion of cortisol-like hormones. The agonist has wide clinical application value for the prevention and treatment of related diseases.

The present invention addresses IBD from the standpoint of mucosal stem cells cloned from defined regions of the gastrointestinal tract. In the case of pediatric Crohn's disease, for example, isolation of those stem cells according to the methods of the present invention reveals a pattern of inflammatory gene expression in stem cells from the terminal ileum and colon that is epigenetically maintained despite months of continuous cultivation in the absence of immune or stromal cells, or of intestinal microbes. Superimposed on this distributed inflammatory phenotype is a differentiation defect that profoundly and specifically alters the mucosal barrier properties of the terminal ileum. The co-existence of diseased and normal stem cells within the same endoscopic biopsies of Crohn's disease patients implicates an epigenetically enforced heterogeneity among mucosal stem cells in the dynamics of this condition.

The invention discloses application of a known compound, namely a thiazole carboxamide derivative (with the CAS number of 933886-42-1), in preparation of a medicine for treating acute lung injury / acute respiratory distress syndrome, the compound is an SLC39A1 agonist, zinc ions entering cells can be effectively increased, and by reducing the expression quantity of lung tissue inflammation genes IL-1beta and TNF-alpha of mice, the lung tissue inflammation genes IL-1beta and TNF-alpha can be effectively inhibited, so that the acute lung injury / acute respiratory distress syndrome can be effectively inhibited, and the acute lung injury / acute respiratory distress syndrome can be effectively inhibited. Therefore, lung cell infiltration in ALI / ARDS mice is reduced, oxidative damage and tissue damage of lung tissue, inflammatory factor expression and cell connection are improved, and a new choice is provided for treatment of ALI / ARDS.

The present invention discloses a bacterial flagellin lacking a hypervariable region structural domain and a preparation method and application thereof. The bacterial flagellin lacking a hypervariable region structural domain is a FliC H7 The amino acid at position 178 to position 497 of the hypervariable region is missing. The present invention constructs a truncated recombinant Escherichia coli flagellin FliC by deleting the middle hypervariable region of flagellin NC In vitro Caco‑2 cell model detection revealed that FliC NC With FliC H7 Similar and good TLR5 receptor activity can activate TLR5 signaling pathway; in vivo, FliC NC Recombinant flagellin can also induce high levels of IgG antibodies against the model antigen FaeG in vivo and inflammatory genes related to humoral and cellular immunity in spleen cells.

The invention designs a preparation method of an active medicinal and edible composite nutrient, and the method comprises the following steps: carrying out initial culture on a ganoderma lucidum monoclonal isolate through a potato dextrose agar plate, and then transferring the ganoderma lucidum monoclonal isolate to a specific liquid culture medium for shake culture; after detecting that the activity of beta-glucosidase reaches 100 mU / mL, centrifuging to take supernatant, and adding rhizoma polygonati, lucid ganoderma and mulberry leaf powder for biotransformation; and inoculating lactobacillus plantarum, adding a freeze-drying protective additive, freeze-drying, and sieving to obtain the active medicinal and edible composite nutrient. According to the method, macromolecular active components of lucid ganoderma, rhizoma polygonati and folium mori are decomposed into small molecules through biotransformation, the problem that a traditional material is poor in intestinal absorption is solved, the prepared active medicinal and edible composite nutrient can restore the number of neutrophils, macrophages and T cells, meanwhile, tnf-alpha, il-12a and ifn-gamma proinflammatory gene expression is up-regulated, and the effect of improving the intestinal absorption rate is achieved. In addition, the natural source is high in safety, and can be used for an immune function regulation scene.

The invention discloses application of spermidine in preparation of a medicine for treating liver injury caused by iron overload, and belongs to the technical field of biological medicine. Experimental verification shows that spermidine can be applied to relieving liver iron ion deposition caused by iron dextran, reducing MDA content, effectively improving liver SOD and CAT enzyme activity and total oxidation resistance, and effectively solving the problems of liver oxidative damage and liver inflammation gene expression up-regulation caused by iron overload. Therefore, spermidine can be developed into a medicine for preventing and treating liver oxidative injury caused by iron overload. The invention finds a new effective substance for prevention and treatment of iron overload.

Provided herein are compositions and methods for ARRDC1-mediated microvesicle-based modulation of inflammatory gene targets, as well as inflammation and inflammatory disorders.

This invention provides a method for preparing and applying a tea polyphenol-crosslinked decellularized diaphragmatic tendon. The tendon is formed by decellularizing porcine diaphragmatic tendon with 1% TNBP and then crosslinking it with tea polyphenols. The tea polyphenol-crosslinked decellularized diaphragmatic tendon can downregulate the expression of apoptosis and inflammatory genes and upregulate the expression of antioxidant genes, exhibiting strong antioxidant properties, mechanical properties, anti-enzymatic properties, and low immunogenicity. It can enhance the antioxidant capacity of cardiomyocytes, promote myocardial tissue vascularization and inhibit fibrosis, inhibit ventricular dilation, improve fibrosis, and promote angiogenesis. It can be used in the preparation of patches for treating myocardial infarction. The tea polyphenol-crosslinked decellularized diaphragmatic tendon provided by this invention has promising applications in the treatment of myocardial infarction.

The receptor for advanced glycation end-products (RAGE) is a multi-ligand receptor member of the immunoglobulin super family which is able to bind Aβ peptide and 3-sheet fibrils. It is expressed in endothelial cells, smooth muscle cells, microglia and neurons, and is implicated in the transport of Aβ through the blood-brain barrier (BBB), oxidative stress-mediated neurotoxicity, and adverse microglia inflammatory responses. The interaction between RAGE and its ligands is thought to result in pro-inflammatory gene activation. Enhanced levels of RAGE ligands in Alzheimer's disease are thought to contribute to the cause of this disorder. Embodiments of the invention use the RAGE multi-ligand site as an anchoring loci for a conversion electron emitting compound rather than as a receptor to intrinsically activate or block inflammation through the RAGE intracellular cascade through activation of the RAGE cytoplasmic tail (ctRAGE) and mammalian diaphanous 1 (DIAPH1).

The invention discloses application of miR-491-5p in sepsis complicated with acute lung injury. The research finds that the miR-491-5p is highly expressed in peripheral blood of a sepsis patient and peripheral blood of a cecum ligation perforation model mouse; the reagent for inhibiting the expression of the miR-491-5p in the hPAEC cell inhibits the expression of pro-inflammatory genes IL-1beta, TNF-alpha, IL-6, CXCL10 and CRP of the hPAEC cell, inhibits the secretion of inflammatory factors IL-1beta, TNF-alpha and IL-6 of the hPAEC cell, promotes the proliferation activity of the hPAEC cell, promotes the migration activity of the hPAEC cell, inhibits the apoptosis of the hPAEC cell, and inhibits the expression of the miR-491-5p in the hPAEC cell. The inhibition of miR-491-5p expression provides a new possible treatment means for the treatment of sepsis complicated with acute lung injury.

The disclosure provides in vivo methods of identifying a lipid nanoparticle that is optimized based on cellular state, delivery profile, or both for delivery into a specific single cell. The lipid nanoparticles contain an identifying DNA barcode and a VHH antibody. An agent simultaneously detects the DNA barcode, the VHH antibody, and endogenous mRNA of the cell to identify one or more viable cells having the DNA barcode and the VHH antibody at a single cell level. The cellular state of viable cells comprising the lipid nanoparticles is determined by sequencing and measuring reduced expression of one or more of an inflammatory gene, a toxicity gene, and a cell state gene compared to a cell not administered the lipid nanoparticle. Based on a favorable expression profile resulting in the cellular state, the lipid nanoparticle is selected.

The embodiment of the invention discloses a modeling method of a periodontitis and preeclampsia combined model, which comprises the following steps of: performing first-stage periodontitis modeling on an experimental mouse through continuous orthodontic ligation for 10 days, and performing continuous annular ligation for 10 days on the basis to perform second-stage periodontitis modeling on the experimental mouse, when the expression level of the inflammation gene of the gingival tissue of the experimental mouse is obviously increased, the periodontitis model of the experimental mouse is successfully established. The method comprises the following steps of: performing preeclampsia modeling on the basis of experimental mice of which periodontitis models are successfully established, randomly dividing pregnant female experimental mice into a model group and a control group, and injecting a nitric oxide synthase inhibition solution into the experimental mice in the model group, when the tail artery systolic pressure of the experimental mice in the model group is increased by at least 20mmHg compared with that of the control group and is continuously increased until the end of pregnancy, the periodontitis and preeclampsia combined model of the experimental mice is successfully established, and the model has important academic value and clinical significance for reducing the occurrence rate of complications in the gestation period and improving maternal and fetal prognosis.

The invention discloses a cynomorium songaricum extract pharmaceutical composition as well as a preparation method and health-care food thereof. A cynomorium songaricum plant material is extracted with an ethanol solution to obtain an extracting solution, the extracting solution comprises multiple cynomorium songaricum triterpenoids, and the multiple cynomorium songaricum triterpenoids jointly act to have remarkable effects on reducing fasting blood-glucose, improving glucose tolerance, improving insulin sensitivity and reducing white fat accumulation; insulin resistance can be improved by inhibiting inflammatory gene expression and reducing inflammatory reaction. The pharmaceutical composition can be used for preventing and treating type 2 diabetes mellitus.

The invention belongs to the technical field of new application of medicines, and particularly relates to a hydroxycinnamic acid derivative as well as a preparation method and application thereof. According to the method, an LPS tracheal instillation induced ARDS model is combined with a hydroxycinnamic acid derivative for treatment, alveolar lavage fluid cell count is measured, and pathological characteristics and inflammation gene expression level of lung tissue are detected; results show that the hydroxycinnamic acid derivative can significantly reduce lung cell infiltration, alleviate lung tissue damage and reduce inflammatory factor expression level.

The invention provides application of a transketolase inhibitor targeting macrophages in preparation of a medicine for preventing and treating fatty liver, and relates to the technical field of biology. In the application provided by the invention, the transketolase inhibitor is selected from at least one of hydroxythiamine, siRNA (small interfering Ribonucleic Acid) of transketolase and shRNA (short hairpin Ribonucleic Acid) of transketolase. Inhibitors that target macrophage transketolase can eliminate or slow down the progression of MAFLD and MASH. After macrophage transketolase is knocked down, the activation level of inflammation can be reduced, metabolism of glucose, lipid and amino acid is reprogrammed, the proportion of alpha-KG / fumarate and alpha-KG / succinate is reduced, DNA hypermethylation is caused, and chromatin accessibility of pro-inflammatory genes in macrophages is reduced. The invention provides a novel application of a targeted macrophage transketolase inhibitor in prevention and treatment of metabolic dysfunction related fatty liver.

The invention belongs to the field of new application of medicines, and particularly relates to application of retinaldehyde in preparation of medicines for treating Toll-like receptor mediated inflammation and the medicines. It is found for the first time that retinaldehyde can be used for inhibiting TLR-mediated inflammatory reaction through targeted activation of OPN3, experimental results show that after all-type retinaldehyde and 9-cis-retinaldehyde are treated, the expression quantity of TNF, IL6, IL18, IFNB1 and ISG15 inflammatory genes in human mononuclear macrophages stimulated by PAM3CSK4, VTX-2337, TNF, Agatolimod and Poly (I: C) can be remarkably reduced, transcriptome experimental data show that the expression quantity of TNF, IL6, IL18, IFNB1 and ISG15 inflammatory genes in the human mononuclear macrophages can be remarkably reduced, and the expression quantity of TNF, IL6, IL18, IFNB1 and ISG15 inflammatory genes can be remarkably The all-form retinaldehyde and the 9-cis-retinaldehyde can activate OPN3 and are used for inhibiting TLR-mediated inflammatory reaction, so that a new thought is provided for treatment of inflammation, and the pharmaceutical application of the retinaldehyde is expanded.

The invention discloses a pomelo fruit crude polysaccharide, and belongs to the technical field of natural product preparation, the pomelo fruit crude polysaccharide is prepared by taking immature pomelo fruit as a raw material through a water extraction alcohol method, and the pomelo fruit crude polysaccharide is composed of pomelo fruit crude polysaccharide 1 (IPFP-1) with the molecular weight of 9187Da and pomelo fruit crude polysaccharide 2 (IPFP-2) with the molecular weight of more than 100kDa. According to the present invention, the IPFP can alleviate mouse disease symptoms caused by DSS, improve colon histopathologic damage, reduce expression of proinflammatory factors TNF-alpha, IL-1beta and IL-6, and increase expression of anti-inflammatory gene IL-10, and the IPFP can inhibit Erk1 / 2 phosphorylation and regulate the composition of intestinal microorganisms, such that the IPFP can significantly improve the anti-inflammatory activity of the mouse, and can significantly improve the anti-inflammatory activity of the mouse. The IPFP provided by the invention can be used as a potential anti-inflammatory component to be applied to ulcerative colitis drugs, and ulcerative colitis can be improved or treated.

The present invention relates to an anti-inflammatory composition and also a method of obtaining the same. The anti-inflammatory composition of the present invention is capable of downregulating the inflammatory genes and comprises an extracellular ribonucleic acid (exRNA) encapsulated in an extracellular vesicle (EV) and other suitable excipients wherein both the extracellular ribonucleic acid (exRNA) and extracellular vesicle (EV) are derived from extra polymeric substances (EPS) of gram-positive non-pathogenic bacteria.